Cancer of the liver

Current Opinion in Gastroenterology

Volumn 12, Issue 3, 1996, Pages 284-289

  Kew, Michael C ^a  

^a UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; ALBUMIN; ALPHA FETOPROTEIN; EPOXIDE HYDROLASE; GLUTATHIONE TRANSFERASE; LIVER PROTEIN; MESSENGER RNA; PROTEIN P53; VIRUS PROTEIN;

CARCINOGENESIS; CELL REGENERATION; CYTOPLASM; EARLY DIAGNOSIS; GENETIC TRANSCRIPTION; HEPATITIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIVER CANCER; LIVER CELL; LIVER CELL CARCINOMA; LIVER METASTASIS; PATHOGENESIS; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHORT SURVEY; VIRUS GENE;

EID: 0030055049     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199605000-00011     Document Type: Short Survey

References (51)

1. Olthoff K, Millis JM, Rososve M, Goldstein LJ, Ramming KP, Busutil RW: Is liver transplantation justified for the treatment of hepatic malignancies? Arch Surg 1990, 125:1296-1298.
2. Yokojama Y, Todo S, Iwatsuki S, Starzl TE: Liver transplantation in the treatment of primary liver cancer. Hepatogastroenterology 1990, 37:188-193.
3. Pichlmayr R, Weimann A, Ringe B: Indication for transplantation in hepatobiliary malignancy. Hepatology 1994, 20(suppl) 33s-40s.
4. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blatt GE: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991, 338:1227-1229.
5. Carr BI, Kar S: An assay for hepatoma micrometastasis: albumin gene expression in peripheral blood from patients with advanced hepatocellular carcinoma [abstract]. Hepatology 1991, 14:A242.
6. Kar S, Carr BI: Detection of liver cells in peripheral blood of patients with advanced-stage hepatocellular carcinoma. Hepatology 1995, 21:403-407. The authors document the frequent presence of albumin mRNA in peripheral blood from patients with advanced HCC but not in patients with early disease. Albumin mRNA was not amplified from the blood of patients with cirrhosis, with tumors metastatic to the liver, or from healthy control subjects.
7. Hillaire S, Barbu V, Boucher E, Moukhtar M, Poupon R: Albumin messenger RNA as a marker of circulating hepatocytes in hepatocellular carcinoma. Gastroenterology 1994, 106:239-242.
8. Matsumura M, Niwa Y, Kato M, Komatsu Y, Shiina S, Kawabe T, Kawase T, Toyshima H, Ihori M, Shiratori Y, Omata M: Detection of α-fetoprotein mRNA, an indicator of hematogenously spreading hepatocellular carcinoma, in the circulation: a possible predictor of metastatic hepatocellular carcinoma. Hepatology 1994, 20:1418-1425.
9. Chou H-C, Sheu J-C, Huang G-T, Wang J-T, Chen D-S: Albumin messenger RNA Is not specific for circulating liver cells. Gastroenterology 1994, 107:630-631. The authors confirm the detection of albumin mRNA in the peripheral blood of healthy individuals using a double round of PCR. This phenomenon probably results from low-level transcription of the α-fetoprotein gene in circulating leukocytes (illegitimate transcription).
10. Chelly J, Concordet JP, Kaplan JC, Kahn A: Illegitimate transcription: transcription of any gene in any cell type. Proc Natl Acad Sci USA 1989, 86:2617-2621.
11. Nambu S, Nishimori H, Saeki M, Higuchi K, Watanabe A: α-Fetoprotein messenger RNA in peripheral blood as a marker of circulating hepatocellular carcinoma cells, Int Hepatol Commun 1995, 5:217-221. In this study, α-fetoprotein mRNA was amplified from the peripheral blood of 38% of Japanese patients with HCC but also from that of 10% of patients with chronic hepatitis.
12. 7 mononuclear cells can be detected. The presence of α-fetoprotein mRNA in patients with HCC correlated with the tumor burden. α-Fetoprotein mRNA was not found in healthy individuals.
13. Newberne PM: Chemical carcinogenesis: mycotoxins and other chemicals to which humans are exposed. Semin Liver Dis 1984, 4:122-132.
14. Ross RK, Yuan J-M, Yu MC, Wogan GN, Qian G-S, Tu JT, Groopman JD, Gao Y-T, Henderson BE: Urinary aflatoxin biomarkers and the risk of hepatocellular carcinoma. Lancet 1992, 339:943-946.
15. 1. Proc Natl Acad Sci U S A 1983, 80:2695-2698.
16. Ozturk M, Bressac B, Puisieux A, Kew M, Volkman M, Bozcall S, Mura JB, De La Monte S, Carlson R, Blum H, Takahashi H: p53 and hepatocellular carcinoma after aflatoxin exposure. Lancet 1991, 338:1356-1359.
17. Aguilar F, Hussain SP, Cerutti P. Aflatoxin B, induces the transversion of Q to T In codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A 1993, 90:8586-8590.
18. Parkin DM, Muir CS, Whelan SL, Gao Y-T, Ferlay J, Powell J: Cancer Incidence in Five Continents. Publication no. 120. Lyon, France: International Agency for Research on Cancer; 1992.
19. Liu YH, Taylor J, Linko P, Lucier JW, Thompson CL: Glutathione-S-transferase mu In human lymphocytes and liver: role In modulating formation of carcinogen-derived DNA adducts. Carcinogenesis 1991, 12:2269-2275.
20. Oesch F, Daly J: Conversion of naphthalene to trans-naphthalene dihydrodiol: evidence for the presence of a coupled aryl mono-oxygenase-epoxide hydrase system in hepatic microsomes. Biochem Biophys Res Commun 1972, 46:1713-1720.
21. Board PG, Coggan M, Johnson P, Ross V, Suzuki T, Webb G: Genetic heterogeneity of the human glutathione-S-transferases: a complex of family genes. Pharmacolol Ther 1990, 48:357-369.
22. Brockmoller J, Kerb R, Drakoulis M, Nitz M, Roots I: Genotype and phenotype of glutathione-S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls. Cancer Res 1993, 53:1004-1011.
23. Skoda RC, Demietre A, McBride OW, Gonzalez FJ, Meyer UA: Human microsomal xenobiotic epoxide hydrolase: complementary DNA sequence, complementary DNA-directed expression in COS-1 cells, and chromosomal hybridization. J Biol Chem 1988, 263:1549-1554.
24. Hassett C, Aicher L, Sidhu S, Omiecinski CJ: Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 1994, 3:421-428.
25. 1. Proc Natl Acad Sci U S A 1995, 92:2384-2387. Mutant alleles of glutathione-S-transferase M1 and EPHX were shown to corre-late with the presence of AFB, adducts in serum, and mutant EPHX alleles with the development of HCC. The specific codon 249 mutation of p53 was found only in patients with one or both high-risk genotypes. HBV carriers with high-risk genotypes are at higher risk of HCC than those with wild-type genotypes.
26. Wang W, London WT, Feitelsohn MJ: Hepatitis B x antigen in hepatitis B virus carrier patients with liver cancer. Cancer Res 1991, 31:4971-4977.
27. Diamantis ID, McGandy CE, Chen T-J, Liaw Y-F, Gudat F, Bianchi LO: Hepatitis B x gene expression in hepatocellular carcinoma. J Hepatol 1992, 15:400-403.
28. Unsal H, Zakicier C, Marcais C, Kew MC, Volkmann M, Zentgraf H, Isselbacher KG, Ozturk M: Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1994, 91:822-626.
29. Kim C, Koike K, Saito I, Miyamura T, Jay G: HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991, 351:317-320.
30. Seto E, Mitchell PJ, Benedict-Yen TS: Transactivation by the hepatltis B virus x protein depends on AP-2 and other transcription factors. Nature 1990, 344:720-74.
31. Feitelsohn MJ, Zhu M, Duan L-X, London WT: Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 1993, 6:1109-1117.
32. Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelsohn MJ, Jay G: Functional inactivation but not structural mutation of p53 causes liver cancer. Nature Genet 1995, 9:41-47. Using a transgenic mouse model expressing only HBx protein, the authors showed that this protein complexed with wild-type p53 protein in the cytoplasm of hepatocytes and completely blocked the transfer of p53 protein into nuclei. Mutations in p53 were found in advanced tumors only.
33. Truant R, Antonovic J, Greenblatt J, Prives C, Cromlish JA: Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivatlon. J Virol 1995, 69:1851-1859. Using protein affinity chromatography and gel mobility shift analysis, the authors confirmed that HBx protein binds directly to wild-type p53 protein. They also showed, in in vivo transfection experiments, that HBx protein binds to and represses transactivation by p53 protein, an activity similar to that of the cellular oncoprotein MDM2.
34. Antonovic J, Lemieux N, Cromlish JA: The 17kDa HBx protein encoded by hepatitis B virus interacts with the activation domains of OCT-1, and functions as a co-activator in the activation and repression of a human U6 promoter. Cell Moll Biol 1993, 39:463-482.
35. Kekule AS, Lauer U, Weiss L, Luber B, Hofschneider PH: Hepatitis B virus transactivator HBx uses a tumor promoter signalling pathway. Nature 1993, 361:742-745.
36. Murakami S, Cheong J, Ohno S, Matsushima S, Kaneko S: Transactivation of human hepatitis B virus x protein, HBx, operates through a mechanism distinct from protein kinase C and okadaic acid activation pathways. Virology 1994, 199:243-246.
37. Kakada S, Kido H, Fukotomi A, Mori T, Koike K: Interaction of hepatitis B virus x protein, tryptase TL2 as an inhibitor. Oncogene 1994, 9:341-348.
38. Beral V, Blum H, Buendia M-A, Craig JR, Dragani TA, GAO YT, Grisham JW, Hall AJ, Kaldor J, Kew MC: Hepatitis viruses. IARC Monogr Eval Carcinog Risks Hum 1994, 59:165-202.
39. Kew MC: Hepatitis C virus and hepatocellular carcinoma. FEBS Microbiol Rev 1994, 14:211-220.
40. Prince AM, Szmuness W, Michon J, Demaille J, Diebolt G, Linhard J, Quenum C, Sankale M: A case/control study of the association between primary liver cancer and hepatitis B infection in Senegal. Int J Cancer 1975, 16:376-383.
41. Vogel CC, Anthony P, Mody N, Barker LF: Hepatitis-associated antigen in Ugandan patients with hepatocellular carcinoma. Lancet 1970, 2:621-624.
42. Kew MC: The possible etiologic role of the hepatitis B virus in hepatocellular carcinoma: evidence from southern Africa. In Advances in Hepatitis Research. Edited by Chisari FV. New York: Masson; 1984:203-215.
43. De Mitri MS, Poussin K, Baccarini P, Pontisso P, D'Errico A, Simon M, Grigioni W, Albert A, Beaugrand F, Pisi E, et al.: HCV-associated liver cancer without cirrhosis. Lancet 1995, 345:413-415. The authors detected HCV RNA in tumor and liver tissue from three patients with HCV-related HCC in whom the nontumorous liver tissue showed only mild portal fibrosis or portal inflammation, or both (Knodell activity score 1 to 2). Their observation provides indirect evidence that HCV may be directly oncogenic.
44. Knodell RG, Ishak RG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman S: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1:431-435.
45. Tsai S-L, Liaw, Y-F, Yen C-T: Cellular immune responses in patients with dual infection with hepatitis B and C viruses: dominant role of hepatitis C virus. Hepatology 1995, 21:908-913.
46. Yu MC, Tong MJ, Coursaget P, Ross RK, Govindarajan S, Henderson BE: Prevalence of hepatitis B and C virus markers in black and white patients with hepatocellular carcinoma in the United States. J Natl Cancer Inst 1990, 82:1038-1041.
47. Kakalamani E, Trichopoulos D, Tzonou N, Zavisanos X, Koumantaki Y, Hatzakis A, Hsieh CC, Hadziyannis S: Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. JAMA 1991, 265:1974-1976.
48. Craig JR, Peters RL, Edmondson HA, Omata M: Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinco-pathologic features. Cancer 1980, 46:372-379.
49. Berman MM, Libbey N, Foster JH: Hepatocellular carcinoma: polygonal cell type with fibrous stroma: an atypical variant with a favorable prognosis. Cancer 1980, 46:1448-1455.
50. Soreide O, Czemiak A, Bradpiece H, Bloom S, Blumgart L: Characteristics of fibrolamellar hepatocellular carcinoma: a study of 9 cases and a review of the literature. Am J Surg 1986, 151:518-523.
51. Stevens WR, Johnson CD, Stephens DH, Nagorney DM: Fibrolamellar hepatocellular carcinoma: stage at presentation and results of aggressive surgical management AJR Am J Roentgenol 1995, 164:1153-1158. In only three of 10 patients with the fibrolamellar variant of HCC was the tumor confined to the liver. The tumor recurred in all of seven patients in whom surgical cure was attempted. Of the 10 patients, five died after a mean survival time of 29 months, two are alive with progression of disease after 2 to 4 months, and three are alive 8 months after re-resection for recurrent tumor.